Those folks with the Apo A1 milano variation seem ripe for further study of the beneficial HDL hypothesis---assuming their cardiovascular risk is really lower, which seems simple to verify.
If I recall correctly, the IP associated with therapeutic use of Apo A1 Milano still resides in the sub-basement of Pfizer as a result of the Esperion purchase?
Market Data 
Markets 
AI
